The second part of my conversation with Drs. Tom Hensing from North Shore Health System in Chicago and David Jackman from Dana Farber Cancer Institute in Boston covered a case of a relatively young, generally healthy woman diagnosed with a lung adenocarcinoma that turned out to be stage IV.  

   Here, we discuss our priorities for molecular testing and how the results of EGFR, KRAS, and EML4-ALK testing would alter our clinical recommendations.  We then discuss the options for this patient, with special focus on how long to continue first line therapy and when and how to transition off of first line treatment into either observation or maintenance therapy.

   Here’s the audio and video podcasts of the discussion, along with the transcript and figures.

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-2-audio-podcast

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-2-transcript

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-2-figures

   This program was sponsored by OSI Pharmaceuticals, who had no input in its content.  We appreciate their support in making this activity possible.

Podcast: Play in new window | Download

Related posts:

ASCO Highlights in Advanced NSCLC, by Dr. Nasser Hanna Here’s the second talk from our recent webinar, partnering with LUNGevit...

Podcast of Webinar by Dr. Lecia Sequist on Acquired Resistance to Oral EGFR Inhibitors A few weeks ago, Dr. Lecia Sequist, Assistant Professor of Medicine at Harvard Medica...

Dr. Ross Camidge on ALK Inhibition, Molecular Screening, and Options after XALKORI Continuing with Dr. Ross Camidge as our focus (see yesterday’s post for ...

Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lun...

Q&A on ALK Inhibitor Therapy, with Drs. Ben Solomon and Ross Camidge Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on th...